A5062681559- Cancer Immunotherapy and Biomarkers
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Bladder and Urothelial Cancer Treatments
- CAR-T cell therapy research
- Ovarian cancer diagnosis and treatment
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
Centre Hospitalier de l’Université de Montréal
2021-2024
PD-L1 expression is used to predict NSCLC response ICIs, but its performance suboptimal. The impact of KRAS mutations in these patients unclear. Studies evaluating co-mutations TP53, STK11 and KEAP1 as well the NLR showed that they may benefit ICIs.
Introduction The incidence of head and neck squamous cell carcinoma (HNSCC) is increasing, particularly among younger populations. It projected that the number new cases will increase by almost 50% 2040, with market revenues expected to triple in same period. Despite recent introduction immune checkpoint inhibitors (ICIs) into therapeutic armamentarium, vast majority patients recurrent and/or metastatic (R/M) HNSCC fail derive durable benefits from systemic therapy.
e16566 Background: EV is a life-prolonging antibody drug conjugate approved and funded in Canada for use patients with mUC after platinum-based chemotherapy immune checkpoint inhibitors (ICI). Recently, has shown comparable real-world results the US, Germany, Switzerland, utilizing mixed public private payer system. We report here outcomes associated monotherapy Canada. Methods: Following ethics approval, retrospective chart review was conducted unresectable locally advanced or who initiated...
e21010 Background: ICIs changed the way NSCLC is treated, but not all patients benefit from it. PD-L1 level used to predict response therapy, its performance sub-optimal. KRAS important in tumorigenesis, impact of mutations treated with unclear. Similarly, studies evaluating co-mutations TP53, STK11 and KEAP1 as well NLR showed that they may ICIs. Methods: We conducted a retrospective study including consenting at CHUM between July 2015 June 2020. OS PFS were compared co-mutation subgroups...